The name Antineoplaston (ANP) comes from their functions in controlling neoplastic cells: Anti means “against”, Neoplastons means “cancer cells”. ANPs are synthesized at SRB manufacturing in Stafford, Texas and is in compliance to strict FDA and EPA regulations.
ANPs were discovered by Stanislaw R. Burzynski, M.D., Ph.D. in 1967 who first identified their anti-cancer properties. ANPs are naturally occurring peptides that demonstrate the ability to re-program cancer cells without destroying normal cells. Due to their low-toxicity and anti-cancer activity, ANPs represent a revolutionary avenue in cancer research. According to Dr. Burzynski, ANPs are components of a complex biochemical sub-immune defence system that controls cancer in the human body. ANPs occur naturally in human blood and are reproduced synthetically for medicinal use.
Dr. Burzynski separated and removed several different types of ANPs from the urine of healthy people. He tested these ANPs on normal and abnormal cells to see their effect and found that some types of ANPs were more effective on more types of abnormal cells than others. He called this type ANP A. He later developed and tested ANPs A1, A2, A3, A4, and A5. He found that A2 had the most effect on tumor cells and named the active ingredient in it A10. Other ANPs followed.
ANPs are unlike common chemotherapy agents currently in use that do not differentiate between cancerous cells and healthy cells. ANPs work on cancer cells to interrupt the activity of the RAS oncogene, which causes cells to divide endlessly. At the same time, ANPs stimulate p53 tumour suppressor genes, which tell the cells to undergo a programmed cellular death. As a result, healthy cells remain unaffected.
Since their discovery in 1967, ANPs have been subjected to extensive scientific research by the Burzynski Research Institute (BRI) and many major national and international research institutes in effort to identify their mechanism of actions and efficacy in cancer treatment. Several institutes confirmed the anti-cancer properties of ANPs, including the National Cancer Institute (1991) and Kurume University Medical School in Japan. Currently, ANPs are used in cancer treatment within clinical trials.
These drugs are comparatively benign. Their toxicity level is very low, comparable to an antihistamine. There are no long-term toxic side effects occurring after treatment like traditional chemotherapeutic agents.
The chemotherapeutic agents in common use today cannot manage cancer for two reasons. First, they destroy healthy cells; therefore these drugs cannot be taken over long periods of time, as can ANPs. Second, no one chemotherapeutic drug can kill all the cancer cells. Just as
there are antibiotic-resistant strains of bacteria, cancer cell types exist that are resistant to specific chemotherapeutic agents. When a chemotherapeutic agent leaves 10% of cancer cells remaining, there may be billions of cells that survive, say, 10 billion. A different chemotherapeutic agent may kill 90% of those cells, leaving behind one billion cells. Still another agent may destroy 90% of those cells, leaving 100 million cells. Of course, all the while these cells are multiplying.
Because they reprogram cancer cells instead of killing them, ANPs do not stop working as do traditional chemotherapy agents. Through this mechanism, ANPs are making cancer a manageable disease.